Monoclonal Antibodies Market for Gastric and Esophageal Cancers to Double by 2019

reportstack

September 15, 2014: Reportstack, the leading provider of market research reports has announced pharma industry report on Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 – Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth report. Due to favorable market conditions in terms of US pricing structures and the anticipated approval of a number of late-stage pipeline drugs, the market value for monoclonal antibodies (mAbs) in gastric and esophageal cancer treatment is expected to double by 2019.

The company’s latest report on Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 forecasts that the market for mAbs in gastric cancer will grow from $256m in 2012 to $501m by 2019, at a Compound Annual Growth Rate (CAGR) of 10%, while the mAbs market for esophageal cancer is expected to climb from $137m in 2012 to $265m by 2019, at a CAGR of 9.9%.

Currently, there is only one mAb – Herceptin – available for the two indications. Primarily marketed for breast cancer, Herceptin gained approval from the US Food and Drug Administration for the treatment of gastric and esophageal cancers in 2010. However, its patent is expected to expire in the European Union in 2014 and in the US by 2019.

Dominic Trewartha, Analyst for GBI Research, says: “Overall, Herceptin is able to improve survival times to a significant extent when compared with chemotherapy alone, without adding a substantial amount of side effects or safety concerns in Human Epidermal growth factor Receptor-2 (HER-2) positive patients. However, its efficacy is not sufficient to bring about a sustained remission in most cases of advanced disease, or to replace conventional chemotherapy completely in earlier stages.”

The pipeline review market for both indications is moderate, with 33 mAbs for gastric cancer and eight for esophageal cancer. The late-stage pipelines also include a number of novel drugs that have shown some clinical and commercial potential. However, none of these products are anticipated to offer significant improvements over existing therapies.

“There is still a need for stronger products with superior efficacy to treat both gastric and esophageal cancers in the metastatic and early settings periods. Also, with a large HER-2 negative patient population that is not eligible for treatment with Herceptin, there is a strong unmet need and opportunity for therapies that are effective in these patients, including those who overexpress HER-2,” Trewartha concludes.

AMG 102 (rilotumumab) – Amgen, IMC-1121B (Ramucirumab) – Eli Lilly and Company, Theraloc (Nimotuzumab) – YM Biosciences, MetMAb (Onartuzumab), Perjeta (pertuzumab), Kadcyla (ado-trastuzumab emtansine) – F. Hoffmann-La Roche are late stage pipeline products mentioned in this report. More details about this report can viewed by visiting Monoclonal Antibodies Market in Gastric and Esophageal Cancers report.

Related  Market Reports from Reportstack:

Gastric Cancer – Pipeline Review, H1 2014

Esophageal Cancer Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

About Reportstack™:

Reportstack is one of the leading distributors of market research reports in the world today. Reportstack provides access to over 50,000 company profiles and their strategic information like SWOT analysis, pipeline review reports, chemical industry reports, deals and partnerships analysis, merger & acquisition activity and new product launches. Reportstack is also a leader in the field of aerospace and defence , consumer retail research, pharma and healthcare market research reports.

Contact Reportstack:

Nathan Gold
Senior Marketing Executive
Phone: +1 888-789-6604
Email: nathan@reportstack.com

Follow us: https://twitter.com/reportstack

To learn more about the monoclonal antibodies market please join us at the European Antibody Congress in Geneva this November.

Leave a Reply

Your email address will not be published. Required fields are marked *